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Summary. Factor X (FX) deficiency is a rare autosomal
recessive disorder. The phenotype and genotype of 15
Iranian patients with FX deficiency from 13 unrelated
families with a high frequency of consanguinity were ana-
lysed. Five different assays identified four patients from three
families with a discrepancy between low-FX coagulant
activity (FX:C) and higher-FX antigen (FX:Ag) (a type II
deficiency). The remaining 11 patients had parallel reduc-
tions of FX:C and FX:Ag (a type I deficiency). Nine different
homozygous candidate mutations were identified, of which
eight were novel. The four type II cases were associated with
an Arg()1)Thr missense mutation in the prepropeptide:
Arg()1) is highly conserved in all vitamin K-dependent
proteins. Four type I mutations (Gly78Asp, Cys81Tyr,
Gly94Arg and Asp95Glu) were localized to the EGF-1 and
EGF-2 domains, for which molecular views showed that the
protein folding would be disrupted. The type I mutation
Gly222Asp was localized in the catalytic domain of FX, and
is sufficiently close to the Asp-His-Ser catalytic triad to dis-
rupt its correct protein folding. The two type I splice site
mutations were IVS1+3, A ﬁ T and IVS2–3, T ﬁ G. These
novel homozygous FX mutations were consistent with their
phenotypes and agree with experimental data from knock-
out mice, indicating that FX is an essential protein for
survival.
Keywords: FX mutations, FX deficiency, FX deficiency
phenotype analysis.
Factor X (FX), the zymogen of the serine protease FXa,
occupies a central position in the coagulation cascade, and
represents the point of convergence between the intrinsic
and extrinsic pathway of blood coagulation. FX is synthes-
ized by the liver and circulates in plasma at a concentration
of 8–10 lg as a two-chain protein with a 17-kDa light
chain disulphide linked to a 45-kDa heavy chain. The light
chain contains a c-carboxyglutamic acid (Gla) domain
necessary for a Ca2+-dependent conformational change
associated with phospholipid binding and two epidermal
growth factor (EGF) domains. The heavy chain contains the
catalytic serine protease domain, which is structurally
homologous to that of other coagulation serine proteases.
Once activated, FX associates with its cofactor factor Va on
a membrane surface to form the prothrombinase complex.
The FX gene (F10) contains eight exons and is located on
chromosome 13q34 (Tuddenham & Cooper, 1994). Each of
the exons of F10 encodes a specific protein domain (Furie &
Furie, 1988). Exon I encodes the signal peptide, exon II the
propeptide and Gla domain, and exon III a short linking
segment of aromatic amino acids. Exons IV and V encode
the two EGF domains, exon VI encodes the activation
peptide at the N-terminus of the heavy chain, and exons VII
and VIII encode the serine protease domain with the
catalytic triad His236, Asp228 and Ser379. FX is synthes-
ized with a 40-residue prepropeptide, which contains the
hydrophobic signal sequence (residues )37 to )22) that
directs the secretion of FX (Leytus et al, 1986). The
propeptide appears to be important in directing intracellular
FX and for post-translational modification (Leytus et al,
1986).
FX deficiency is a rare haemorrhagic condition, inherited
as an autosomal recessive trait. Patients with severe FX
deficiency are the most seriously affected among patients
with rare coagulation defects (Peyvandi & Mannucci,
1999). The more frequent symptoms in FX-deficient
patients are haemarthroses, muscle haematomas, umbilical
cord bleeding, and gastrointestinal and central nervous
system (CNS) bleeds (Peyvandi et al, 1998). To date, 39
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missense mutations and seven deletions in the FX gene have
been reported (see Cooper et al, 1997; Perry, 1997; Miyata
et al, 1998a,b; Nobauer-Huhmann et al, 1998; Zama et al,
1999; Bereczky et al, 2000; Millar et al, 2000; Deam et al,
2001; Iijima et al, 2001; Simioni et al, 2001, and refer-
ences therein). To extend the knowledge on naturally
occurring mutations that cause FX deficiency, 15 patients
from 13 unrelated Iranian families with severe FX defici-
ency have been examined using molecular analysis and
three-dimensional structure analysis. The great majority of
these patients were born from first cousin consanguineous
marriages. Therefore, in contrast with the majority of
previously reported studies, this study reports data from
homozygous patients, enabling us to define the clinical
phenotype associated with the presence of one abnormal
allele without interference or compensation by the other
allele. Further to previously described mutations, most of
which have been located within the catalytic serine
protease domain, we describe the effect of four novel
mutations in the two EGF domains and one in the serine
protease domain.
PATIENTS AND METHODS
Patients. Fifteen FX-deficient patients from 13 unrelated
families (12 men and 4 women, aged 2–55 years) were
studied. All families were of Iranian origin. Eleven out of the
15 patients were the offspring of marriages between first
cousins. Informed consent for investigation was obtained
from all individuals. To establish the type and severity of
bleeding symptoms, we used a questionnaire that was
specially designed to collect focused and objective informa-
tion from patients (Lak et al, 2000). Severe bleeders were
classified as those who had spontaneous and/or life-threat-
ening bleeding episodes, such as haemarthroses, muscle
haematomas, and umbilical cord, gastrointestinal and CNS
haemorrhages. Mild bleeders were those who bled only after
trauma or surgery or who had bleeding problems such as
epistaxis or menorrhagia. Non-bleeders were those with no
history of bleeding.
Factor X assays. Five different assays were used on
samples from patients and their related family members.
The FX coagulation activity (FX:C) assay methods
involved a one-stage prothrombin time (PT) and an
activated partial thromboplastin time (APTT) bioassay,
both performed on an ACL3000 automated analyser
(Instrumentation Laboratory, Milan, Italy), a manual one-
stage Russell viper venom (RVV) assay (Diagen, Thame,
UK), and a two-stage chromogenic assay (Chromogenics,
Instrumentation Laboratory, Milan, Italy). The FX:C
values were calculated using, as a reference, plasma
pooled from 40 normal individuals (20 men, and 20
women who were not pregnant and who were not taking
oral contraceptives). The reference plasma was assigned
an arbitrary FX:C-value of 100%. In Iran, FX:C was
assayed with a PT assay method using rabbit thrombo-
plastin and FX:C-deficient plasma from patients with
severe deficiency and no FX:C inhibitor. Levels of FX
antigen (FX:Ag) were measured using an in-house
enzyme immunoassay. Plastic 96-well microtitre plates
were coated overnight at room temperature with rabbit
anti-human FX polyclonal antibody (Dako, Ely, UK)
diluted 1:800. After removal of the coating solution with
a washing buffer, a standard curve was constructed with
serial dilutions of pooled normal plasma in the buffer, and
samples were incubated for 2 h at room temperature. The
plates were then washed and reincubated with a 1:650
dilution of horseradish peroxidase conjugated rabbit anti-
human FX polyclonal antibody used in the coating step
for 2 h at room temperature. The enzymatic activity was
detected by ortho-phenylene-diamine; the reaction was
stopped with a solution of H2SO4 and optical density
was determined at 492 nm. Results from this in-house
enzyme immunoassay were compared with those from a
commercial enzyme immunoassay kit (Dako, Ely, UK)
using the same coating and labelling antibody and found
to give similar FX:Ag values in each patient plasma
tested. FX:Ag levels were calculated using as a reference
the same pooled plasma used for the FX:C assays.
Sensitivity of the assay was 0Æ1% of normal FX:Ag levels
(i.e. 100 ng/ml), the intra-assay coefficient of variation
was 5% and the interassay coefficient of variation, 8%.
DNA analysis. Genomic DNA was extracted from peri-
pheral blood leucocytes according to standard protocols.
Following DNA extraction, the coding region, intron/exon
boundaries and the 5¢ and 3¢ UTR of the FX gene were
amplified by polymerase chain reaction (PCR) and screened
for mutations by single strand conformation polymorphism
analysis (SSCP) (Orita et al, 1989). Direct sequencing of
amplified DNA fragments was used to confirm and identify
the presence of any mutations.
Polymerase chain reaction. Amplification reactions were
carried out in 30-ll volumes and comprised 100 ng of DNA,
10 pmoles of each oligonucleotide primer, 240 lmol/l of
each dNTP, 1Æ5 mmol/l MgCl2, 50 mmol/l KCl, 10 mmol/l
Tris-HCl pH 8Æ3 and 2 units of Taq polymerase (PE, Applied
Biosystems, UK). Reactions were denatured at 95C for
5 min, and then 35–40 cycles of amplification were
performed. On the last cycle, the extension time was
increased to 10 min. The primer sequences and amplifica-
tion parameters are available on request.
Single strand conformation polymorphism (SSCP) analy-
sis. In total, 10 ll of the final PCR product was mixed with
25 ll of denaturation buffer (95% formamide, 0Æ05%
Bromophenol blue, 10 mmol/l NaOH), denatured for
10 min at 94C, then placed on ice for 2 min. Then,
20 ll of each denatured sample was loaded onto a 10%
polyacrylamide gel (acrylamide:bisacrylamide) in 1· Tris-
borate-EDTA buffer (0Æ09 mmol/l Tris-borate, 2 mmol/l
EDTA). Gels were pre-run at 150 V at 15C for 45 min in
1· Tris-borate-EDTA buffer before loading, then electro-
phoresis was carried out at 250 V for 5–6 h at 15C
(fragment size 250–300 bp). DNA fragments were visu-
alized by silver staining (Promega, Milan, Italy). The ratios
of acrylamide:bisacrylamide were different for the different
FX exons and information is available on request. Supple-
mentation of the gels with urea was used only in the study
of exon 7 and the promoter.
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Sequence analysis. PCR products were purified (Qiagen
Purification Kit, Milan, Italy) and directly sequenced using
an ABI Prism310 genetic analyser automated sequencer
(PE Applied Biosystems, Milan, Italy) with the same primers
used for the amplification reactions, except for exon 1,
which required a different sequencing primer. Any muta-
tion identified by direct sequencing was confirmed by repeat
sequencing and restriction enzyme digestion if associated
with the creation or loss of a specific restriction enzyme site.
To confirm that our genetic variants were not frequent
polymorphisms, all mutations were also investigated in 200
alleles in an Iranian control population.
Structural analysis of FX mutations. The crystal coordi-
nates of FX were obtained from the Protein Data Bank
(codes 1ezq, 1f0r, 1f0s, 1fax, 1hcg, 1xka, 1xkb) (Padm-
anabhan et al, 1993; Brandstetter et al, 1996; Kamata
et al, 1998; Maignan et al, 2000). Protein structures
were visualized using the insight II 98Æ0 program
package (Biosym/MSI, San Diego, CA, USA) on Silicon
Graphics INDY workstations, using Crystal Eyes stereo
glasses for detailed inspections. The quantitative assign-
ment of the experimentally observed main-chain secon-
dary structure of each protein was made using the DSSP
(Definition of Secondary Structure of Proteins)
programme (Kabsch & Sander, 1983); Fig 1 shows the
a-helix and b-strand contents (denoted H and E respect-
ively) and other types of secondary structures including
loops and turns (T, S, B and G). The quantitative
Fig 1. Protein sequence and structure analysis of human Factor X. The 39 previously known mutations are identified by asterisks (*); six of the
eight novel mutations in this study are identified by dollar symbols ($), and the three catalytic triad residues are identified by hatches (#). The Gla,
EGF and catalytic serine protease domain assignments are shown above the sequence numbering for FX (SWISSPROT code P00742). In the Gla
domain, Gla residues are identified by g. The DSSP output shows the consensus secondary structures from seven crystal structures of FX when
these correspond to experimentally observed structures. No output is shown if no structures were present. The b-strands in the two EGF domains
(denoted by E in the DSSP output) are each labelled B1-B4, and those in the serine protease subdomains are labelled A-O. The a-helices (denoted
by H) in the serine protease subdomains are labelled A1-A3. The comparer output shows a value (0–9), which represents the consensus solvent
accessibility of each side-chain in FX. Exposed residues are identified by values of 2–9, and buried residues by values of 0 or 1.
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assignment of solvent-exposed residue side-chains was
made using the comparer programme by the Lee and
Richards method of using a water molecule radius of
1Æ4 A˚ (Lee & Richards, 1971; Sali & Blundell, 1990).
Side-chains were defined as solvent-exposed if their
accessibilities ranged between 20% and 100% (values
2–9 in Fig 1) and buried if these ranged between 0%
and 19% (values of 0 and 1 in Fig 1).
Splice-site computer analysis. A computer-assisted analysis
of splice-sites sequences and prediction for these sequences
utilized the Berkley Drosophila Genome Project human
database website (http://www.fruitfly.org/seq_tools/
spliceAbst.html).
RESULTS
Phenotype analysis
Table I summarizes the FX assays for each of 15 patients
from the 13 unrelated families and the severity of their
bleeding symptoms. In 11 out of 15 patients, low levels of
both FX:C by all four methods and FX:Ag were observed,
and these were assigned as type I deficiencies. In the
remaining four patients (B1 and B2 from the same kindred;
C and D from unrelated kindred), low levels of FX:C were
observed in contrast to the normal levels of FX:Ag, and
these were assigned as type II deficiencies (i.e. the presence
of a dysfunctional FX molecule). Only patient M had FX
levels below the assay sensitivity (1%) using all assays for
FX:C and FX:Ag.
The results obtained by the five assays showed marked
variation in the sensitivity of the chromogenic assay
compared with the three coagulation assays for individual
samples. The pattern across the five methods was consis-
tent within family members (data not shown). In 9 out of
15 patients, the FX:C result at diagnosis (in the referring
Iranian hospital) was confirmed by our subsequent
testing. Two patients (H1 and H2) had a higher level of
coagulant activity measured by the RVV test compared
with PT, APTT, chromogenic and FX:Ag levels. In six
patients (D, F, G, H1 and I) with severe bleeding
symptoms (umbilical cord bleeding, recurrent haematomas
and haemarthroses, haematuria, gastrointestinal bleed-
ing), there was a discrepancy between the FX assay
results at diagnosis in Iran and the subsequent value
obtained in our laboratory. This discrepancy is probably
due to traces of exogenous FX introduced by replacement
therapy, which is frequently needed in these severely
affected patients (Peyvandi et al, 1998). Four out of 15
severely affected patients (B1, B2, C and D) had normal
borderline chromogenic activity and antigen levels in
contrast to their low PT, APTT and RVV coagulation
assays, indicating a type II deficiency. Eight samples from
severely affected patients (E, F, G, H1, H2, I, J and K) had
measurable but reduced chromogenic activity, and the
patients would have been misdiagnosed if the chromo-
genic assay had been used alone. In two patients (A and
L) only two out of the five FX assays (APTT and FX:Ag)
were carried out because of limited amounts of available
plasma.
Novel mutations
Six of the eight previously unreported mutations were
missense mutations and two were splice-site mutations, all
of which were homozygous.
The mutation Arg()1)Thr present in exon 2 encoding the
prepropeptide was present in four patients from three
unrelated families (kindred B, C and D) who had low FX:C
levels associated with normal borderline levels of FX:Ag and
chromogenic assays (type II deficiency). A small discrepancy
between PT, APTT and RVV values of patients B1, B2 and
C, D was observed. This discrepancy could be the result of
small traces of the last substitutive treatment before sample
collection. These patients need frequent treatment because
they suffer from recurrent haemarthroses, haematomas and
umbilical cord bleeding.
Two novel mutations, Gly78Asp and Cys81Tyr, present
in exon 4 encoding EGF-1, were detected in three families
with type I deficiencies (E, F and G). Patient E with
Gly78Asp mutation presented with severe bleeding after
circumcision, recurrent haemarthroses, haematomas, hae-
maturia and mucosal bleeding. This patient required
frequent replacement therapy with fresh frozen plasma,
factor IX complex concentrates and red cells.
Two associated novel mutations Gly94Arg and Asp95-
Glu, present in exon 5 and encoding the EGF-2 domain,
were identified in two siblings (H1 and H2) who were not
born from a consanguineous marriage. Both H1 and H2
were homozygous for these two mutations and both
patients presented with recurrent haematomas, haemarth-
roses, epistaxes and oral bleeding. Both patients came from
a small village of an Iranian Turkish ethnic group.
The last novel missense mutation (Gly222Asp), found in
two apparently unrelated kindred (J and K), was in exon 7
encoding the catalytic domain of FX and was associated
with a type I phenotype. Patient J has recurrent haemato-
mas and haemarthroses, haematuria and epistaxis. Patient
K, with the same mutation, presented with epistaxis and
gastrointestinal bleeding that required several blood trans-
fusions.
The first splice-site mutation was localized at nucleotide
+73 (+1 denotes the first nucleotide of the ATG start codon,
numbering in accordance with GenBank, accession no.
12738260, 2001). In patient A, a homozygous A ﬁ T
transition within intron A (IVS1+3) was associated with a
parallel reduction in both FX:Ag and FX:C (APTT). The
8-year-old boy with this mutation suffered from umbilical
cord bleeding, haematoma, epistaxis and CNS bleeding.
The second splice-site mutation was localized at nucleotide
+15599. Patient L showed a homozygous T ﬁ G transver-
sion within intron B (IVS2–3), associated with type I
deficiency. This patient suffered from recurrent knee hae-
marthroses, haematomas, epistaxes and oral bleeding.
Previously reported mutation
The mutation Gly204Arg in exon 7, identified in patient I,
had been reported previously in a one-year-old boy, whose
ethnic group was not given, with severe bleeding history
and reduced FX:C and FX:Ag (Bereczky et al, 2000). Earlier
molecular modelling suggested that the mutant protein is
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unstable and may cause intracellular degradation (Bereczky
et al, 2000). None of the novel or previously reported
mutations was found in the control Iranian population. In
one patient with severe bleeding and type I deficiency (M),
no mutations were found. Patient M died following a CNS
bleed at the age of 2 years.
DISCUSSION
The large number of homozygous candidate FX mutations
presented here has significantly increased our knowledge on
gene mutations associated with FX deficiency, the most
severe of the rare recessively transmitted coagulation
disorders. The identification of eight novel mutations in
this study leads to a total of 47 known mutations in the FX
gene (Fig 1).
In previous cases of FX deficiency, many patients were
found to be heterozygous or doubly heterozygous for
mutations in the FX gene (Cooper et al, 1997), making it
difficult to assess the effect resulting from each allele. Here,
we analysed the phenotype and genotype in a group of 15
patients with homozygous FX deficiency. The results of
clotting assays in this study highlight the problems associ-
ated with screening FX deficiency. The PT, APTT and RVV-
based assays showed similar sensitivities to both mild and
severe reductions in FX. The chromogenic assay usually
gave results similar to the FX:Ag level, but could not be used
as a single assay because of the risk of an undiagnosed
dysfunctional FX deficiency. In two patients from the same
family (H1 and H2), a measurable coagulant activity by the
RVV assay was found, which was in contrast with the
undetectable FX:C activity measured by either a PT or
APTT-based assay; the chromogenic or antigenic assays
were also reduced (Simioni et al, 2001).
The genotype study by SSCP screening combined with
direct sequencing of PCR products identified nine candi-
date mutations in the human FX gene in 13 kindred, of
which eight were novel (Table I). In agreement with
previously characterized mutants of FX, none of the
mutations was predicted to lead to the production of a
truncated protein or no protein at all, and this is
consistent with the hypothesis that a complete absence
of FX is fatal (Dewerchin et al, 2000). FX–/– knockout
mice present a lethal phenotype, which demonstrates the
importance of FX function in embryonic and postnatal
survival. Molecular graphics analyses based on crystal
structures of FX were used to explain the effect of each of
the novel mutations in comparison with the previously
known ones.
Arg)1Thr mutation
The vitamin K-dependent c-glutamyl carboxylase catalyses
the post-translational modification of specific glutamic acid
residues to c-carboxyglutamic acid (Gla) residues in the Gla
domain (Stanley et al, 1999a). This modification is essential
for blood coagulation. In all known vitamin K-dependent
proteins, the mechanism by which the carboxylase recog-
nizes its substrate is believed to be through its initial binding
to an essential conserved 18-residue propeptide. This
propeptide is proteolytically removed before the formation
of mature FX (Furie & Furie, 1991). Mutations at the )1
position are not believed to affect carboxylation, but rather
to disable propeptide cleavage and processing (Ware et al,
1989). The naturally occurring substitution at Arg-1Thr in
four patients from three unrelated families is likely to inhibit
this cleavage, and will produce only dysfunctional FX
protein. Sequences alignment of the vitamin K-dependent
protein propeptide demonstrated that Arg-1 is highly
conserved (Stanley et al, 1999b). Naturally occurring mis-
sense mutations affecting the codon for the basic amino acid
of the propeptidase recognition sequence of factor IX (Arg
)1Ser) (Giannelli et al, 1994), protein C (Arg )1Cys/His/
Ser) (Miyata et al, 1995; Reitsma et al, 1995) and protein S
(Arg-1His) (Gandrille et al, 1995) all result in secretion of
gene products with severely reduced functions.
Four EGF mutations
Out of the 39 previously known missense mutations shown
in Fig 1, 23 occur in the serine protease domain, whereas
only 13 occur in the Gla and EGF domains. Our present
study has almost doubled the number of known mutations
in the EGF domains of FX. The EGF-1 and EGF-2 domains
are thought to be important not only in binding Ca2+ but
also in maintaining the correct conformation of FXa. In the
EGF-1 domain, the Gly78Asp and Cys81Tyr mutations
correspond to exposed (Gly78) and buried (Cys81) residues
at loop conformations that appear to be important for the
correct folding of the EGF domain (Figs 1 and 2A). This is
consistent with their identification as type I disorders. The
replacement of the small Gly residue by a bulkier residue
may prevent the EGF-1 domain from folding correctly. The
loss of one out of the six Cys residues will prevent the correct
formation of the three-disulphide bridges that are essential
for the folding of the EGF-1 domain. In the EGF-2 domain,
the simultaneous replacement of Gly94Arg and Asp95Glu
occurs in a pocket containing two other acidic groups and
three basic groups from the EGF-1, EGF-2 and catalytic
domains (Fig 2B). The introduction of an extra charged
residue in this region is likely to affect the correct folding of
FX and, in turn, its secretion. This interpretation is in
accordance with its assignment as a type I disorder. Of
interest is that this double mutant shows only a mild
reduction in coagulation activity by the RVV assay, and
expression analysis will be required to verify the effect of this
mutation.
Catalytic domain mutation
The catalytic activity of FX resides in the serine protease
domain, in which the active site is formed from the triad of
residues, His236, Asp282 and Ser379. The Gly222Asp
mutation corresponds to the replacement of a tiny fully
buried residue at the centre of a buried b-strand C by a
larger charged residue adjacent to the catalytic triad (Fig 1).
Although the introduction of this charged group may
perturb the catalytic triad (Fig 2C), it is more likely that the
insertion of a charged hydrophilic residue into the protein
core will disrupt its correct folding. This interpretation is
consistent with its type I assignment.
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Splice site mutations
The use of the Berkely Drosophila Genome Project human
database predicted that mutation IVS1+3 would probably
result in the complete abolition of the donor-splicing site in
mutant, whereas the IVS2–3 mutation would change the
efficiency of the splicing from 1Æ00 (score for wild type FX) to
0Æ63 (score for mutant FX). These analyses accounted for
the type I assignment of these two novel mutations.
Patients who are severely deficient in FX (with a reduced
procoagulant activity and antigen level) are severe bleeders,
and require much FX replacement therapy (Peyvandi et al,
1998). Therefore, prenatal diagnosis should be performed in
pregnancies at risk in families with at least one member
affected by this coagulation disorder, and knowledge of the
underlying mutation is essential to achieve this goal.
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